HUE042978T2 - Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok - Google Patents
Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékokInfo
- Publication number
- HUE042978T2 HUE042978T2 HUE12746093A HUE12746093A HUE042978T2 HU E042978 T2 HUE042978 T2 HU E042978T2 HU E12746093 A HUE12746093 A HU E12746093A HU E12746093 A HUE12746093 A HU E12746093A HU E042978 T2 HUE042978 T2 HU E042978T2
- Authority
- HU
- Hungary
- Prior art keywords
- cyclopenta
- pyrrole
- dihydro
- bacterial
- substituted
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- -1 cyclopenta [c] pyrrole-substituted 3,4-dihydro-1H- [1,8] naphthyridone Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119 | 2011-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE042978T2 true HUE042978T2 (hu) | 2019-07-29 |
Family
ID=46650549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12746093A HUE042978T2 (hu) | 2011-08-10 | 2012-08-10 | Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906923B2 (OSRAM) |
| EP (1) | EP2742045B1 (OSRAM) |
| JP (2) | JP5921687B2 (OSRAM) |
| KR (1) | KR101996862B1 (OSRAM) |
| CN (2) | CN105461684B (OSRAM) |
| AR (1) | AR087508A1 (OSRAM) |
| AU (1) | AU2012293621B2 (OSRAM) |
| BR (1) | BR112014003063B1 (OSRAM) |
| CA (1) | CA2842518C (OSRAM) |
| CL (1) | CL2014000289A1 (OSRAM) |
| DK (1) | DK2742045T3 (OSRAM) |
| EA (1) | EA201490438A1 (OSRAM) |
| ES (1) | ES2721658T3 (OSRAM) |
| HU (1) | HUE042978T2 (OSRAM) |
| IL (1) | IL230549A (OSRAM) |
| JO (1) | JO3611B1 (OSRAM) |
| MX (1) | MX348128B (OSRAM) |
| PE (1) | PE20141410A1 (OSRAM) |
| PH (1) | PH12014500317A1 (OSRAM) |
| TR (1) | TR201905537T4 (OSRAM) |
| TW (1) | TWI568731B (OSRAM) |
| UA (1) | UA111210C2 (OSRAM) |
| UY (1) | UY34253A (OSRAM) |
| WO (1) | WO2013021054A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2881681T3 (es) | 2011-08-10 | 2021-11-30 | Janssen Sciences Ireland Unlimited Co | 3,4-Dihidro-1H-[1,8]naftiridinonas sustituidas con piperidinilo antibacterianas |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| WO2014023814A1 (en) * | 2012-08-10 | 2014-02-13 | Janssen R&D Ireland | New antibacterial compounds |
| US9540324B2 (en) | 2013-09-26 | 2017-01-10 | Luc Therapeutics, Inc. | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| SMT201900517T1 (it) | 2017-03-20 | 2019-11-13 | Forma Therapeutics Inc | Composizioni di pirrolopirrolo come attivatori di piruvato chinasi (pkr) |
| WO2019177975A1 (en) | 2018-03-12 | 2019-09-19 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| CN113226356B (zh) | 2018-09-19 | 2025-03-04 | 诺沃挪第克健康护理股份公司 | 活化丙酮酸激酶r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| BR112021009106A2 (pt) * | 2018-11-12 | 2021-08-10 | Debiopharm International S.A. | compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| JP2024509998A (ja) * | 2021-03-17 | 2024-03-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| JP4961084B2 (ja) | 1999-10-08 | 2012-06-27 | アフィニアム・ファーマシューティカルズ・インコーポレイテッド | Ｆａｂｉ阻害剤 |
| EP1225894B1 (en) | 1999-10-08 | 2006-07-05 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| PE20010635A1 (es) | 1999-10-08 | 2001-08-15 | Smithkline Beecham Corp | Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas |
| DK1560584T3 (da) | 2001-04-06 | 2009-05-18 | Affinium Pharm Inc | Fab I inhibitorer |
| KR101299399B1 (ko) * | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | 치료제, 및 그의 제조 및 사용 방법 |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
| EP2125802A4 (en) * | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| US8846711B2 (en) | 2009-11-18 | 2014-09-30 | Fab Pharma S.A.S. | Heterocyclic acrylamides and their use as pharmaceuticals |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| ES2881681T3 (es) | 2011-08-10 | 2021-11-30 | Janssen Sciences Ireland Unlimited Co | 3,4-Dihidro-1H-[1,8]naftiridinonas sustituidas con piperidinilo antibacterianas |
| AU2012293618B2 (en) | 2011-08-10 | 2017-04-20 | Janssen Sciences Ireland Uc | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en not_active Ceased
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh not_active IP Right Cessation
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/en active
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko active Active
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en active Active
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 PH PH1/2014/500317A patent/PH12014500317A1/en unknown
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja not_active Expired - Fee Related
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en active Active
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE042978T2 (hu) | Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok | |
| AP3336A (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| SMT201600354B (it) | Composti di beta-lattame sostituiti da ammidina, loro preparazione ed uso come agenti antibatterici | |
| EP2875029B8 (en) | 5,5-heteroaromatic anti-infective compounds | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2762476A4 (en) | 1,2,4-triazine-6-carboxamide derivative | |
| ZA201205788B (en) | 1,2,4-triazine-4-amine derivatives | |
| PT2620436T (pt) | Profármaco de derivado de carbamoilo piridona policíclica substituída | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| ZA201206630B (en) | Hetaryl-[1,8]naphthyridine derivatives | |
| IL240078A0 (en) | Isooxazole derivatives useful as antibacterial agents | |
| ZA201306542B (en) | 7-azaindole derivatives | |
| EP2634186A4 (en) | naphthyridine | |
| EP2774926A4 (en) | morphinan | |
| BR112013023056A2 (pt) | derivados de oxaespiro [2,5] octano e análogos | |
| ZA201404074B (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| IL232717A0 (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| ZA201305983B (en) | C-4" position substituted macrolide derivative | |
| ZA201306229B (en) | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| MY165626A (en) | 1,2,4,-triazolone derivative | |
| ME02908B (me) | Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije | |
| ZA201304074B (en) | Pyrazino[2,3-d]isoxazole derivative | |
| PL2851075T3 (pl) | Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu | |
| BR112013013282A2 (pt) | compostos de oxazolo[5,4-b]piridin-5-ila |